GSK agrees more government orders for H1N1 vaccine

pharmafile | October 7, 2009 | News story | Sales and Marketing GSK, h1n1, vaccines 

GSK has agreed another 22 government orders for its adjuvanted swine-flu vaccine – an extra 149 million doses on top of its previous agreements.

The new deals bring the total orders GSK has received to 440 million doses, making it one of the major global suppliers of H1N1 vaccine.

GSK says it is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.

In early August, it confirmed that it had contracts in place to supply 291 million doses of the vaccine and had a variety of agreements in place with the US government to supply pandemic products worth $250 million.

Since then, another 22 orders have been agreed to supply a further 149 million doses of the vaccine, and discussions continue with governments for further supplies.

GSK is using adjuvant technology, which boosts the potency of antigen, meaning the same volume of vaccine can be split into more doses.

Novartis is also using this mechanism on its own vaccine, though other suppliers such as Baxter and Sanofi Pasteur are not.

GSK, along with Novartis, has seen its jabs approved by the European regulator and the company says first supplies of its vaccine are being shipped to governments this week. Further shipments of the vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010.

Deliveries are contingent on a number of factors including government import and export regulations, regulatory and packaging approvals, and the testing required by reference laboratories.

GSK said it would continue to provide regular updates to governments relating to delivery schedules to support them in planning their vaccination programmes.


Related Content


GSK shares data from global shingles survey

GSK has announced data from its new global survey about shingles. The data suggests that …


GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials 

GSK has announced that in 2024 it intends to start phase 3 trials of a …

Latest content